miR-16 inhibits NLRP3 inflammasome activation by directly targeting TLR4 in acute lung injury

Acute lung injury (ALI) is the leading cause of human death, and it is widely accepted that the runaway inflammation is an important risk for the development of ALI. In the present study, we aimed to investigate the effect of miR-16 on lipopolysaccharide-induced acute lung injury in mice, especially...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Biomedicine & pharmacotherapy 2019-04, Vol.112, p.108664-108664, Article 108664
Hauptverfasser: Yang, Yuan, Yang, Feng, Yu, Xinqiao, Wang, Beibei, Yang, Yang, Zhou, Xiaoyu, Cheng, Rui, Xia, Shiwen, Zhou, Xiaoguang
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 108664
container_issue
container_start_page 108664
container_title Biomedicine & pharmacotherapy
container_volume 112
creator Yang, Yuan
Yang, Feng
Yu, Xinqiao
Wang, Beibei
Yang, Yang
Zhou, Xiaoyu
Cheng, Rui
Xia, Shiwen
Zhou, Xiaoguang
description Acute lung injury (ALI) is the leading cause of human death, and it is widely accepted that the runaway inflammation is an important risk for the development of ALI. In the present study, we aimed to investigate the effect of miR-16 on lipopolysaccharide-induced acute lung injury in mice, especially focusing on Toll-like receptor 4 (TLR4) and NF-kB signaling pathway as well as NOD-like receptor protein 3 (NLRP3) inflammasome activation. We established in vivo and in vitro model of ALI using LPS and demonstrated that miR-16 expression was down-regulated in lung tissue as well as A549 cells after 8 h of LPS treatment. Furthermore, when miR-16 levels in lung tissues were up-regulated by miR-16 agomir, it was confirmed that the mRNA and protein levels of NF-κB, NLRP3 inflammasome, and inflammatory factors were decreased by the miR-16 by directly targeting TLR4. We also treated A549 cells with miR-16 mimics and anti-miR-16 to confirm the results. Overall, our experiments showed that miR-16 protects against acute lung injury in mice by regulating the TLR4/ NF-κB pathway and attenuating inflammatory response. This work suggests a potential novel therapeutic approach to combat ALI.
doi_str_mv 10.1016/j.biopha.2019.108664
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2184155107</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0753332218377850</els_id><sourcerecordid>2184155107</sourcerecordid><originalsourceid>FETCH-LOGICAL-c408t-34973ed5ca2224c8449b005777b88df5d56ab0c05c92cf543682b778044d10d73</originalsourceid><addsrcrecordid>eNp9kEtLxDAQx4Mouj6-gUiPXrpOXk16EUR8waKy6FFCmqaapY81SYX99mapevQ0ZPj9ZyY_hE4xzDHg4mI1r9yw_tBzArhMLVkUbAfNcMkhLwDELpqB4DSnlJADdBjCCgB4QeU-OqAgJCspn6G3zi1zXGSu_3CViyF7XCyfaXo2re46HYbOZtpE96WjG_qs2mS189bEdpNF7d9tdP179rJYshRJ4Bht1o6p5frV6DfHaK_RbbAnP_UIvd7evFzf54unu4frq0VuGMiYU1YKamtuNCGEGclYWaVbhRCVlHXDa17oCgxwUxLTcEYLSSohJDBWY6gFPULn09y1Hz5HG6LqXDC2bXVvhzEogiXDnGPYomxCjR9C8LZRa-867TcKg9qKVSs1iVVbsWoSm2JnPxvGqrP1X-jXZAIuJ8Cmf34561UwzvbGTr5UPbj_N3wDxauJog</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2184155107</pqid></control><display><type>article</type><title>miR-16 inhibits NLRP3 inflammasome activation by directly targeting TLR4 in acute lung injury</title><source>Elsevier ScienceDirect Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Yang, Yuan ; Yang, Feng ; Yu, Xinqiao ; Wang, Beibei ; Yang, Yang ; Zhou, Xiaoyu ; Cheng, Rui ; Xia, Shiwen ; Zhou, Xiaoguang</creator><creatorcontrib>Yang, Yuan ; Yang, Feng ; Yu, Xinqiao ; Wang, Beibei ; Yang, Yang ; Zhou, Xiaoyu ; Cheng, Rui ; Xia, Shiwen ; Zhou, Xiaoguang</creatorcontrib><description>Acute lung injury (ALI) is the leading cause of human death, and it is widely accepted that the runaway inflammation is an important risk for the development of ALI. In the present study, we aimed to investigate the effect of miR-16 on lipopolysaccharide-induced acute lung injury in mice, especially focusing on Toll-like receptor 4 (TLR4) and NF-kB signaling pathway as well as NOD-like receptor protein 3 (NLRP3) inflammasome activation. We established in vivo and in vitro model of ALI using LPS and demonstrated that miR-16 expression was down-regulated in lung tissue as well as A549 cells after 8 h of LPS treatment. Furthermore, when miR-16 levels in lung tissues were up-regulated by miR-16 agomir, it was confirmed that the mRNA and protein levels of NF-κB, NLRP3 inflammasome, and inflammatory factors were decreased by the miR-16 by directly targeting TLR4. We also treated A549 cells with miR-16 mimics and anti-miR-16 to confirm the results. Overall, our experiments showed that miR-16 protects against acute lung injury in mice by regulating the TLR4/ NF-κB pathway and attenuating inflammatory response. This work suggests a potential novel therapeutic approach to combat ALI.</description><identifier>ISSN: 0753-3322</identifier><identifier>EISSN: 1950-6007</identifier><identifier>DOI: 10.1016/j.biopha.2019.108664</identifier><identifier>PMID: 30784935</identifier><language>eng</language><publisher>France: Elsevier Masson SAS</publisher><subject>Acute lung injury (ALI) ; Mice ; MicroRNA-16 ; NLRP3 inflammasome ; TLR4</subject><ispartof>Biomedicine &amp; pharmacotherapy, 2019-04, Vol.112, p.108664-108664, Article 108664</ispartof><rights>2019</rights><rights>Copyright © 2019. Published by Elsevier Masson SAS.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c408t-34973ed5ca2224c8449b005777b88df5d56ab0c05c92cf543682b778044d10d73</citedby><cites>FETCH-LOGICAL-c408t-34973ed5ca2224c8449b005777b88df5d56ab0c05c92cf543682b778044d10d73</cites><orcidid>0000-0002-0903-5627</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0753332218377850$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30784935$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yang, Yuan</creatorcontrib><creatorcontrib>Yang, Feng</creatorcontrib><creatorcontrib>Yu, Xinqiao</creatorcontrib><creatorcontrib>Wang, Beibei</creatorcontrib><creatorcontrib>Yang, Yang</creatorcontrib><creatorcontrib>Zhou, Xiaoyu</creatorcontrib><creatorcontrib>Cheng, Rui</creatorcontrib><creatorcontrib>Xia, Shiwen</creatorcontrib><creatorcontrib>Zhou, Xiaoguang</creatorcontrib><title>miR-16 inhibits NLRP3 inflammasome activation by directly targeting TLR4 in acute lung injury</title><title>Biomedicine &amp; pharmacotherapy</title><addtitle>Biomed Pharmacother</addtitle><description>Acute lung injury (ALI) is the leading cause of human death, and it is widely accepted that the runaway inflammation is an important risk for the development of ALI. In the present study, we aimed to investigate the effect of miR-16 on lipopolysaccharide-induced acute lung injury in mice, especially focusing on Toll-like receptor 4 (TLR4) and NF-kB signaling pathway as well as NOD-like receptor protein 3 (NLRP3) inflammasome activation. We established in vivo and in vitro model of ALI using LPS and demonstrated that miR-16 expression was down-regulated in lung tissue as well as A549 cells after 8 h of LPS treatment. Furthermore, when miR-16 levels in lung tissues were up-regulated by miR-16 agomir, it was confirmed that the mRNA and protein levels of NF-κB, NLRP3 inflammasome, and inflammatory factors were decreased by the miR-16 by directly targeting TLR4. We also treated A549 cells with miR-16 mimics and anti-miR-16 to confirm the results. Overall, our experiments showed that miR-16 protects against acute lung injury in mice by regulating the TLR4/ NF-κB pathway and attenuating inflammatory response. This work suggests a potential novel therapeutic approach to combat ALI.</description><subject>Acute lung injury (ALI)</subject><subject>Mice</subject><subject>MicroRNA-16</subject><subject>NLRP3 inflammasome</subject><subject>TLR4</subject><issn>0753-3322</issn><issn>1950-6007</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp9kEtLxDAQx4Mouj6-gUiPXrpOXk16EUR8waKy6FFCmqaapY81SYX99mapevQ0ZPj9ZyY_hE4xzDHg4mI1r9yw_tBzArhMLVkUbAfNcMkhLwDELpqB4DSnlJADdBjCCgB4QeU-OqAgJCspn6G3zi1zXGSu_3CViyF7XCyfaXo2re46HYbOZtpE96WjG_qs2mS189bEdpNF7d9tdP179rJYshRJ4Bht1o6p5frV6DfHaK_RbbAnP_UIvd7evFzf54unu4frq0VuGMiYU1YKamtuNCGEGclYWaVbhRCVlHXDa17oCgxwUxLTcEYLSSohJDBWY6gFPULn09y1Hz5HG6LqXDC2bXVvhzEogiXDnGPYomxCjR9C8LZRa-867TcKg9qKVSs1iVVbsWoSm2JnPxvGqrP1X-jXZAIuJ8Cmf34561UwzvbGTr5UPbj_N3wDxauJog</recordid><startdate>20190401</startdate><enddate>20190401</enddate><creator>Yang, Yuan</creator><creator>Yang, Feng</creator><creator>Yu, Xinqiao</creator><creator>Wang, Beibei</creator><creator>Yang, Yang</creator><creator>Zhou, Xiaoyu</creator><creator>Cheng, Rui</creator><creator>Xia, Shiwen</creator><creator>Zhou, Xiaoguang</creator><general>Elsevier Masson SAS</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-0903-5627</orcidid></search><sort><creationdate>20190401</creationdate><title>miR-16 inhibits NLRP3 inflammasome activation by directly targeting TLR4 in acute lung injury</title><author>Yang, Yuan ; Yang, Feng ; Yu, Xinqiao ; Wang, Beibei ; Yang, Yang ; Zhou, Xiaoyu ; Cheng, Rui ; Xia, Shiwen ; Zhou, Xiaoguang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c408t-34973ed5ca2224c8449b005777b88df5d56ab0c05c92cf543682b778044d10d73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Acute lung injury (ALI)</topic><topic>Mice</topic><topic>MicroRNA-16</topic><topic>NLRP3 inflammasome</topic><topic>TLR4</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yang, Yuan</creatorcontrib><creatorcontrib>Yang, Feng</creatorcontrib><creatorcontrib>Yu, Xinqiao</creatorcontrib><creatorcontrib>Wang, Beibei</creatorcontrib><creatorcontrib>Yang, Yang</creatorcontrib><creatorcontrib>Zhou, Xiaoyu</creatorcontrib><creatorcontrib>Cheng, Rui</creatorcontrib><creatorcontrib>Xia, Shiwen</creatorcontrib><creatorcontrib>Zhou, Xiaoguang</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Biomedicine &amp; pharmacotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yang, Yuan</au><au>Yang, Feng</au><au>Yu, Xinqiao</au><au>Wang, Beibei</au><au>Yang, Yang</au><au>Zhou, Xiaoyu</au><au>Cheng, Rui</au><au>Xia, Shiwen</au><au>Zhou, Xiaoguang</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>miR-16 inhibits NLRP3 inflammasome activation by directly targeting TLR4 in acute lung injury</atitle><jtitle>Biomedicine &amp; pharmacotherapy</jtitle><addtitle>Biomed Pharmacother</addtitle><date>2019-04-01</date><risdate>2019</risdate><volume>112</volume><spage>108664</spage><epage>108664</epage><pages>108664-108664</pages><artnum>108664</artnum><issn>0753-3322</issn><eissn>1950-6007</eissn><abstract>Acute lung injury (ALI) is the leading cause of human death, and it is widely accepted that the runaway inflammation is an important risk for the development of ALI. In the present study, we aimed to investigate the effect of miR-16 on lipopolysaccharide-induced acute lung injury in mice, especially focusing on Toll-like receptor 4 (TLR4) and NF-kB signaling pathway as well as NOD-like receptor protein 3 (NLRP3) inflammasome activation. We established in vivo and in vitro model of ALI using LPS and demonstrated that miR-16 expression was down-regulated in lung tissue as well as A549 cells after 8 h of LPS treatment. Furthermore, when miR-16 levels in lung tissues were up-regulated by miR-16 agomir, it was confirmed that the mRNA and protein levels of NF-κB, NLRP3 inflammasome, and inflammatory factors were decreased by the miR-16 by directly targeting TLR4. We also treated A549 cells with miR-16 mimics and anti-miR-16 to confirm the results. Overall, our experiments showed that miR-16 protects against acute lung injury in mice by regulating the TLR4/ NF-κB pathway and attenuating inflammatory response. This work suggests a potential novel therapeutic approach to combat ALI.</abstract><cop>France</cop><pub>Elsevier Masson SAS</pub><pmid>30784935</pmid><doi>10.1016/j.biopha.2019.108664</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-0903-5627</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0753-3322
ispartof Biomedicine & pharmacotherapy, 2019-04, Vol.112, p.108664-108664, Article 108664
issn 0753-3322
1950-6007
language eng
recordid cdi_proquest_miscellaneous_2184155107
source Elsevier ScienceDirect Journals; EZB-FREE-00999 freely available EZB journals
subjects Acute lung injury (ALI)
Mice
MicroRNA-16
NLRP3 inflammasome
TLR4
title miR-16 inhibits NLRP3 inflammasome activation by directly targeting TLR4 in acute lung injury
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T11%3A38%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=miR-16%20inhibits%20NLRP3%20inflammasome%20activation%20by%20directly%20targeting%20TLR4%20in%20acute%20lung%20injury&rft.jtitle=Biomedicine%20&%20pharmacotherapy&rft.au=Yang,%20Yuan&rft.date=2019-04-01&rft.volume=112&rft.spage=108664&rft.epage=108664&rft.pages=108664-108664&rft.artnum=108664&rft.issn=0753-3322&rft.eissn=1950-6007&rft_id=info:doi/10.1016/j.biopha.2019.108664&rft_dat=%3Cproquest_cross%3E2184155107%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2184155107&rft_id=info:pmid/30784935&rft_els_id=S0753332218377850&rfr_iscdi=true